Literature DB >> 12738247

The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.

Zandong Yang1, Meng Chen, Lawrence B Fialkow, Justin D Ellett, Runpei Wu, Volker Brinkmann, Jerry L Nadler, Kevin R Lynch.   

Abstract

FTY720 is a novel immune regulatory drug derived from the fungal sphingosine analog ISP-1 (myriocin). FTY720 causes a redistribution of lymphocytes from circulation to secondary lymphoid tissues. Type 1 diabetes is an autoimmune disorder caused by cellular-mediated destruction of insulin-producing pancreatic beta cells in the islets of Langerhans. Indeed, local infiltration of islets by mononuclear cells is the hallmark of Type 1 diabetes. Based on both FTY720's action and the involvement of cellular infiltration in the disease progression, we tested FTY720 for its ability to prevent autoimmune diabetes in diabetes-prone, nonobese diabetic (NOD) mice. We found that treatment with FTY720 completely prevented NOD mice from developing autoimmune diabetes. The FTY720-treated animals showed both reduced numbers of circulating lymphocytes and sharply diminished cellular infiltration of pancreatic islets. These results suggest that FTY720 may be effective in prevention of autoimmune diabetes or in slowing its progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738247     DOI: 10.1016/s1521-6616(02)00054-2

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

1.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Authors:  Alaa S Awad; Michael D Rouse; Konstantine Khutsishvili; Liping Huang; W Kline Bolton; Kevin R Lynch; Mark D Okusa
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

Review 2.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Prominence of central sphingosine-1-phosphate receptor-1 in attenuating aβ-induced injury by fingolimod.

Authors:  Masoumeh Asle-Rousta; Zeynab Kolahdooz; Leila Dargahi; Abolhassan Ahmadiani; Sanaz Nasoohi
Journal:  J Mol Neurosci       Date:  2014-09-20       Impact factor: 3.444

Review 4.  The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases.

Authors:  Yang Mao-Draayer; Jeffrey Sarazin; David Fox; Elena Schiopu
Journal:  Clin Immunol       Date:  2016-11-23       Impact factor: 3.969

5.  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.

Authors:  Margarita Dominguez-Villar; Khadir Raddassi; Ann Caroline Danielsen; Joseph Guarnaccia; David A Hafler
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

6.  The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors.

Authors:  Shawn G Payne; Carole A Oskeritzian; Rachael Griffiths; Preeti Subramanian; Suzanne E Barbour; Charles E Chalfant; Sheldon Milstien; Sarah Spiegel
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

Review 7.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 8.  The role of sphingosine-1-phosphate and its receptors in asthma.

Authors:  John J Ryan; Sarah Spiegel
Journal:  Drug News Perspect       Date:  2008-03

9.  Regulation of learning and memory by meningeal immunity: a key role for IL-4.

Authors:  Noël C Derecki; Amber N Cardani; Chun Hui Yang; Kayla M Quinnies; Anastasia Crihfield; Kevin R Lynch; Jonathan Kipnis
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

Review 10.  [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Authors:  J Klatt; H-P Hartung; R Hohlfeld
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.